DEVELOPMENT PORTFOLIO

American Gene Technologies™ (AGT) is building a rich product pipeline based on its lentiviral vector platform. Our three lead programs are well into the laboratory phase and scheduled to move into the clinic over the coming months.

Genetic medicine can be used to modify properties of cancer cells, causing them to become powerful stimulators of anti-tumor immunity. AGT has developed proprietary genetic medicines carried by lentivirus vectors, that enter tumor cells, reduce cellular defenses against T cell immunity, and stimulate a potent, broad-acting T cell response capable of tumor killing. Our ImmunoToxTM technology coupled with our Transient LentiVectorTM make our platform a powerful, safe and reusable development resource.